European Journal of Clinical Pharmacology 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Posting of clinical trial results and other critical information from completed medicines trials on ClinicalTrials.gov
ConclusionFuture interventions should be considered to encourage timely posting of trial results and information. (Source: European Journal of Clinical Pharmacology)
Source: European Journal of Clinical Pharmacology - August 15, 2023 Category: Drugs & Pharmacology Source Type: research
Risk factors for thrombocytopenia in patients receiving linezolid therapy: a systematic review and meta-analysis
ConclusionsA variety of risk factors related to the occurrence of LIT were revealed in our analysis. Early identification of these factors could help patients improve clinical outcomes. (Source: European Journal of Clinical Pharmacology)
Source: European Journal of Clinical Pharmacology - August 14, 2023 Category: Drugs & Pharmacology Source Type: research
Will artificial intelligence chatbots replace clinical pharmacologists? An exploratory study in clinical practice
ConclusionThe interest of chatbot assistance needs to be confirmed or rejected through further studies conducted in other pharmacovigilance centers. (Source: European Journal of Clinical Pharmacology)
Source: European Journal of Clinical Pharmacology - August 11, 2023 Category: Drugs & Pharmacology Source Type: research
What do older patients know about their medication? A cross-sectional, interview-based pilot study
ConclusionOur study showed that medication knowledge of older patients was overall satisfying. Awareness of sick day rules, however, was poor. Future studies should evaluate the clinical benefits of sick day rules and ways of better communicating sick day rules to patients. In this regard, general practitioners may play a decisive role. (Source: European Journal of Clinical Pharmacology)
Source: European Journal of Clinical Pharmacology - August 10, 2023 Category: Drugs & Pharmacology Source Type: research
Oxytocin treatment for core symptoms in children with autism spectrum disorder: a systematic review and meta-analysis
ConclusionWhile the therapeutic value of oxytocin in treating core symptoms of ASD in children is not fully established, the results of this meta-analysis indicate a potential moderate effect. However, further studies with larger sample sizes and more robust RCTs are needed to directly demonstrate the efficacy of oxytocin. Future research should also focus on effect size and outcome evaluation accuracy while minimizing bias in RCT experiments. (Source: European Journal of Clinical Pharmacology)
Source: European Journal of Clinical Pharmacology - August 4, 2023 Category: Drugs & Pharmacology Source Type: research
Prevention of contrast induced-acute kidney injury using coenzyme Q10 in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention
ConclusionsOur research ’s findings proposed CoQ10 supplementation as an adjuvant to saline hydration as a preventive approach against CI-AKI.Trial registrationThe trial was registered at Iranian Registry of Clinical Trials (https://www.irct.ir/trial/60435, identifier code: IRCT20120215009014N414). Registration date: 2021 –12-29. (Source: European Journal of Clinical Pharmacology)
Source: European Journal of Clinical Pharmacology - August 1, 2023 Category: Drugs & Pharmacology Source Type: research
Influence of non-osteoporotic treatments in patients on active anti-osteoporotic therapy: evidence from the OSTEOMED registry
ConclusionThe potential beneficial or detrimental effects of the different drugs evaluated on fracture risk are masked by treatment with anabolic or antiresorptive drugs that have a more potent action on bone metabolism, with two exceptions: letrozole and oral corticosteroids. These findings may have important clinical implications, as patients receiving these treatments are not fully protected by bisphosphonates, which may imply the need for more potent anti-osteoporotic drugs such as denosumab or teriparatide. (Source: European Journal of Clinical Pharmacology)
Source: European Journal of Clinical Pharmacology - July 29, 2023 Category: Drugs & Pharmacology Source Type: research
LABA/LAMA versus LABA/ICS fixed-dose combinations in the prevention of COPD exacerbations: a modeling analysis of literature aggregate data
ConclusionsThis study showed that not all LABA/LAMA FDCs were superior to LABA/ICS FDCs in safety and in preventing moderate or severe exacerbations in patients with stable COPD, providing important quantitative information for COPD-related guidelines. (Source: European Journal of Clinical Pharmacology)
Source: European Journal of Clinical Pharmacology - July 29, 2023 Category: Drugs & Pharmacology Source Type: research
Dipeptidyl-peptidase-4 inhibitors have anti-inflammatory effects in patients with type 2 diabetes
ConclusionThis meta-analysis demonstrated that DPP-4 inhibitors can significantly attenuate low-grade inflammatory state in patients with T2DM. In addition to improving glycemic control, DDP-4 inhibitors might offer extra therapeutic value by controlling inflammation.Graphical Abstract (Source: European Journal of Clinical Pharmacology)
Source: European Journal of Clinical Pharmacology - July 26, 2023 Category: Drugs & Pharmacology Source Type: research
Impact of tofogliflozin on hepatic outcomes: a systematic review
ConclusionOverall, an improvement in levels of hepatic parameters was observed in T2DM patients with concurrent liver disorders. However, a large number of clinical trials are needed to prove the efficacy of tofogliflozin on hepatic outcomes in patients with T2DM. (Source: European Journal of Clinical Pharmacology)
Source: European Journal of Clinical Pharmacology - July 18, 2023 Category: Drugs & Pharmacology Source Type: research
Therapeutic drug monitoring of voriconazole and CYP2C19 phenotype for dose optimization in paediatric patients
ConclusionsThe VRC plasma trough concentration is significantly influenced by the CYP2C19 phenotype. The recommended maintenance dose for pediatric patients may not be appropriate for Chinese patients. To increase the probability of achieving the therapeutic range for VRC plasma trough concentration, the administration of VRC should consider the age of paediatric patients and the presence of CYP2C19 polymorphisms. (Source: European Journal of Clinical Pharmacology)
Source: European Journal of Clinical Pharmacology - July 17, 2023 Category: Drugs & Pharmacology Source Type: research
Optimisation of warfarin-dosing algorithms for Han Chinese patients with CYP2C9*13 variants
ConclusionOur study showed that the algorithm-predicted doses should be lowered forCYP2C9*13 carriers. Inclusion of theCYP2C9*13 variant in the warfarin-dosing algorithm tends to predict the warfarin maintenance dose more accurately and improves the efficacy and safety of warfarin administration in Han Chinese patients. (Source: European Journal of Clinical Pharmacology)
Source: European Journal of Clinical Pharmacology - July 17, 2023 Category: Drugs & Pharmacology Source Type: research
